10-Q: Organon Q3 Earnings Hit by Nexplanon Sales Probe, Leadership Shake-Up

Organon reported a significant drop in Q3 net income and EPS, alongside a leadership overhaul and internal investigation findings regarding improper Nexplanon sales practices.

Summary

• Net income for the three months ended September 30, 2025, decreased 55.5% to $160 million, compared to $359 million in Q3 2024.
• Diluted earnings per share (EPS) for Q3 2025 fell 55.8% to $0.61, down from $1.38 in Q3 2024.
• For the nine months ended September 30, 2025, net income decreased 48% to $392 million, compared to $755 million in the prior year period.
• Diluted EPS for the nine months ended September 30, 2025, decreased 48.6% to $1.50, from $2.92 in the prior year period.
• Worldwide sales for Q3 2025 increased 1% to $1.6 billion, while sales for the nine months ended September 30, 2025, decreased 2% to $4.7 billion.
• An internal investigation found that the former Chief Executive Officer and leader of the U.S. commercial organization applied inappropriate pressure on two U.S. wholesalers to purchase greater quantities of Nexplanon than demand warranted, and waived inventory management fees.
• Without these improper sales practices, consolidated revenue for fiscal year 2024 and certain quarterly periods would have fallen short of guidance and external expectations.
• The company identified material weaknesses in its internal control over financial reporting as of December 31, 2024, and September 30, 2025, related to 'tone at the top' and 'information and communication'.
• Kevin Ali resigned as CEO and Board member on October 26, 2025; Joseph Morrissey was appointed Interim CEO, Carrie S. Cox as Executive Chair, and Robert Essner as Lead Independent Director.
• The company terminated the employment of its Head of U.S. Commercial & Government Affairs on October 26, 2025.
• The company acquired U.S. regulatory and commercial rights for Tofidence (tocilizumab-bavi) biosimilar from Biogen for an upfront payment of $51 million in March 2025.
• The Jada System is being divested to Laborie Medical Technologies Corporation for up to $465 million, expected to close in early 2026.
• Restructuring costs of $88 million were incurred for the nine months ended September 30, 2025, primarily due to a 6% headcount reduction, expected to result in approximately $200 million in annual savings.
• The company repurchased and cancelled $242 million of its 5.125% notes due 2031, resulting in a $42 million pre-tax gain, and repaid the NovaQuest Funding Agreement for a $4 million pre-tax gain.

Sentiment

Score: 3

Explanation: The significant decline in net income and EPS, coupled with the disclosure of material weaknesses in internal control over financial reporting and the forced resignation of the CEO due to improper sales practices, indicates a highly negative sentiment. While there are some positive product developments and debt management, these are overshadowed by the governance and financial performance issues.

Positives

• Worldwide sales for the three months ended September 30, 2025, increased by 1% to $1.6 billion, with a positive impact of approximately $36 million from favorable foreign exchange rates.
• Vtama sales showed strong performance due to the acquisition of Dermavant and the launch of its atopic dermatitis indication in the U.S. and plaque psoriasis treatment in Canada.
• Hadlima sales are ramping up since its U.S. launch in July 2023, with modest increases in international markets.
• Emgality sales increased significantly by 74% in Q3 and 82% for the nine months, following the acquisition of distribution and promotion rights from Lilly.
• The company successfully repurchased and cancelled $242 million of its 5.125% notes due 2031, resulting in a pre-tax gain on extinguishment of debt of $42 million.
• The NovaQuest Funding Agreement, valued at $103 million, was voluntarily repaid and terminated, resulting in a pre-tax gain of $4 million.
• Acquired the Oss Biotech manufacturing facility in the Netherlands from Merck for $25 million, enhancing fertility drug substance production.
• FDA approved Bildyos and Bilprevda (denosumab-nxxp) biosimilars to Prolia and Xgeva, and the European Commission granted marketing authorization, leading to recognition of $30 million in intangible assets.
• Restructuring initiatives, including an approximate 6% headcount reduction, are expected to result in approximately $200 million of annual savings.
• Working capital increased to $2.02 billion as of September 30, 2025, from $1.63 billion at December 31, 2024.
• Net cash flows provided by operating activities increased to $559 million for the nine months ended September 30, 2025, compared to $549 million in the prior year.

Negatives

• Net income for Q3 2025 decreased 55.5% to $160 million, and diluted EPS decreased 55.8% to $0.61.
• Net income for the nine months ended September 30, 2025, decreased 48% to $392 million, and diluted EPS decreased 48.6% to $1.50.
• Gross profit decreased 7% in Q3 and 9% for the nine months, primarily due to increased manufacturing costs, unfavorable price, product mix, and foreign exchange translation.
• An internal investigation revealed improper sales practices for Nexplanon, where wholesalers were pressured to purchase excess inventory, leading to material weaknesses in internal control over financial reporting.
• Without these improper sales practices, consolidated revenue for fiscal year 2024 and certain quarterly periods would have fallen short of guidance and external expectations.
• The cessation of the identified improper sales practices for Nexplanon is expected to adversely impact Q4 2025 sales.
• Nexplanon sales decreased 8% in Q3 due to lower demand and decreased funding of government programs in the United States.
• The Phase 2 ELENA proof-of-concept study for OG-6219 in endometriosis-related pain did not meet its primary efficacy endpoint, leading to the discontinuation of the clinical development program.
• Singulair sales decreased significantly (37% in Q3, 30% in 9M) due to lower demand outside the U.S. and price reductions in Japan and China.
• Atozet sales declined substantially (24% in Q3, 35% in 9M) primarily due to loss of exclusivity in France, Spain, and Japan.
• Dulera sales declined (31% in Q3, 22% in 9M) due to the loss of a customer contract, increased discount rate pressure, and supply constraints expected to continue into Q4.
• Renflexis sales declined (2% in Q3, 9% in 9M) due to competitive pressure and unfavorable discount rates in the U.S.
• Ontruzant sales for the nine months declined 25% due to competitive pressure in the U.S. and unfavorable pricing and lower tendered volume from Brazil's Ministry of Health.
• The company recognized $6 million in acquired in-process research and development and milestones related to exiting an agreement with Suzhou Centergene Pharmaceuticals due to changes in the fertility landscape in China.
• Exchange losses increased for both the three and nine months ended September 30, 2025, due to unfavorable movements in certain foreign currencies relative to the U.S. dollar.
• Net cash used in investing activities increased by 50% to $325 million for the nine months, primarily due to increased milestone payments.
• Net cash used in financing activities increased by 30.8% to $374 million for the nine months.

Risks

• The company identified material weaknesses in its internal control over financial reporting related to 'tone at the top' and 'information and communication' due to improper Nexplanon sales practices, which could impact the accuracy and timeliness of future financial reports.
• The internal investigation and related findings may result in additional expenses, litigation, inquiries from the SEC or other regulatory authorities, and potential monetary fines, penalties, and reputational harm.
• Dependence on key products like Nexplanon, Arcoxia, Singulair, and the ezetimibe family means any adverse events affecting these products or their markets could significantly impact sales, results of operations, or cash flows.
• Continued loss of exclusivity (LOE) for products like Atozet and potential failure to retain market exclusivity or obtain additional exclusivity for Nexplanon pose significant revenue risks.
• Ongoing and increasing generic competition for products such as NuvaRing, Renflexis, and Ontruzant will continue to exert downward pressure on sales and pricing.
• Global pricing pressures from governments and payors, including legislative or regulatory pricing reforms, drug formularies, and initiatives like Medicare drug price negotiation and Most-Favored-Nation (MFN) pricing, could materially adversely affect the business.
• Supply chain disruptions, increased costs of supply, manufacturing, packaging, and operations, and difficulties with third-party suppliers could impact product availability and profitability, as seen with Dulera.
• Geopolitical developments, global trade issues (e.g., tariffs), shifting government policies, and worsening macroeconomic conditions (e.g., inflation, interest rates, recessionary pressures, foreign currency volatility) could impact business and working capital.
• The company is involved in various legal proceedings, including product liability lawsuits (Fosamax, Nexplanon/Implanon), patent litigation (Nexplanon), and securities/stockholder derivative litigation, with uncertain outcomes and potential for significant costs and damages.
• The company is obligated to indemnify Merck for liabilities relating to products transferred during the spinoff, including competition investigations, which could result in significant financial exposure.
• The divestiture of the Jada System is subject to regulatory approvals and other customary closing conditions, and there is no assurance that these will be met or that the transaction will close as expected.

Future Outlook

The company expects continued impact from Volume-Based Procurement (VBP) in China on its general medicines product portfolio for the next several quarters. A significant decline in Atozet sales is anticipated in 2025 due to loss of exclusivity, and NuvaRing sales are expected to continue declining due to generic competition. The cessation of identified improper Nexplanon sales practices is projected to adversely impact fourth-quarter 2025 sales. While the FDA needs more time to review Nexplanon's 5-year duration indication, the three-month extension is not expected to materially affect the original late 2025 or early 2026 launch timeline. The divestiture of the Jada System is expected to close in early 2026. The company is evaluating the impacts of the One Big Beautiful Bill Act (OBBBA) on its U.S. cash tax liability and income tax provision for 2026 and beyond. An ongoing initiative to optimize the manufacturing and supply network, including separating the supply chain from Merck through 2031, is expected to incur associated costs.

Management Comments

• "We have been and will continue to adapt our business and sales strategies to address this changing landscape in order to achieve our business objectives and remain competitive."
• "The Company ceased the identified sales practices for wholesalers described in the Recent Developments section above, which will adversely impact the fourth quarter 2025 sales."
• "Though we were recently notified that the agency needs more time to complete the review of our submission [for Nexplanon 5-year duration indication], the PDUFA three-month extension is not material to our original timeline, which was to launch in late 2025 or early 2026."
• "The process of designing and maintaining effective internal control over financial reporting is a continuous effort that requires management to anticipate and react to changes in our business, economic, and regulatory environments and to expend significant resources."
• "Management continues to evaluate the effectiveness of these remedial measures and expects to continue implementing improvements to the Companys internal control over financial reporting."

Industry Context

The pharmaceutical industry is experiencing increasing global pricing pressures from governments and payors, including legislative reforms, drug formularies, and initiatives like Medicare drug price negotiation and Most-Favored-Nation (MFN) pricing, which directly impact Organon's commercial strategy and pricing flexibility. The company's strategic focus on biosimilars, with launches like Tofidence, Hadlima, Bildyos, and Bilprevda, aligns with the broader industry trend of expanding competition in the immunology and oncology sectors. However, the significant impact of loss of exclusivity (LOE) on products like Atozet and ongoing generic competition for NuvaRing highlight the challenges faced by companies with mature product portfolios. Regulatory developments, such as the OBBBA and U.S. presidential executive orders on drug pricing, underscore the evolving and complex regulatory landscape that pharmaceutical companies must navigate.

Management Changes

Corporate Governance

Legal Proceedings

• Fosamax Litigation: Approximately 844 federal cases, 1,532 New Jersey state cases, 1 Pennsylvania state case, and 209 California state cases alleging femur fractures. A Master Settlement Agreement was signed with NJ state and federal plaintiffs' lawyers (confidential, non-material). The U.S. Supreme Court denied a writ of certiorari, allowing 844 federal cases to proceed.
• Nexplanon/Implanon Product Liability: Two filed and 56 unfiled (tolled) Implanon cases, one Nexplanon case in California, and 17 international cases alleging injuries related to the use of these products.
• Nexplanon Patent Litigation: Organon sued Xiromed Pharma Espana, S.L. for patent infringement after they filed an Abbreviated New Drug Application (ANDA) for a generic Nexplanon, triggering a 30-month stay of regulatory approval.
• Securities Class Action Lawsuits: Two lawsuits filed by stockholders alleging materially false and misleading statements regarding the company's capital allocation strategy (including quarterly dividends) and debt reduction strategy.
• Stockholder Derivative Lawsuits: Two lawsuits alleging breach of fiduciary duties by officers and directors based on the same allegations as the securities lawsuits; these actions have been consolidated and deferred pending resolution of motions to dismiss in the securities cases.
• Governmental Proceedings: Subsidiaries may receive inquiries and be subject to preliminary investigation activities from competition and/or other governmental authorities, potentially leading to formal proceedings, monetary fines, and/or remedial undertakings. Organon indemnifies Merck for liabilities related to products transferred during the spinoff.

Related Party Transactions

• Manufacturing and supply agreements with Merck & Co., Inc., where Organon manufactures certain products for Merck and vice versa. As of September 30, 2025, $162 million was due from Merck in Accounts receivable and $401 million was due to Merck in Accounts payable.
• Acquisition of the Oss Biotech manufacturing facility in the Netherlands from Merck & Co., Inc. in July 2025 for $25 million, plus $71 million for the purchase of remaining inventory at the site.
• Exit from an interim operating model agreement with Merck in the United States related to the Follistim AQ product during the fourth quarter of 2023.

Stakeholder Impact

• Shareholders: Significant decrease in net income and EPS, coupled with material weaknesses in internal controls and management changes, could negatively impact investor confidence and share price. Potential for future litigation costs and reputational harm. A quarterly dividend of $0.02 per share was declared.
• Employees: Approximately 6% headcount reduction as part of restructuring initiatives, leading to severance costs but expected annual savings. Termination of the Head of U.S. Commercial & Government Affairs.
• Customers/Wholesalers: Improper sales practices for Nexplanon involved pressuring wholesalers to purchase excess inventory and waiving inventory management fees. The cessation of these practices is expected to impact future sales.
• Regulatory Authorities: Voluntary contact with SEC staff regarding the internal investigation, with potential for future inquiries or proceedings, indicating increased regulatory scrutiny.
• Management: Former CEO and Head of U.S. Commercial & Government Affairs removed due to findings of inappropriate pressure and conduct. New interim leadership appointed to address governance issues.
• Creditors: The company remains in compliance with all financial covenants under its Senior Credit Agreement. Active debt management through repurchases and repayments demonstrates commitment to financial obligations.

Next Steps

• Continue to evaluate the impacts of the One Big Beautiful Bill Act (OBBBA) on U.S. cash tax liability and income tax provision for 2026 and beyond.
• Implement measures designed to improve internal control over financial reporting and remediate the identified material weaknesses.
• Continue to monitor legal defense costs and review the adequacy of associated reserves for ongoing litigation.
• Launch Nexplanon's 5-year duration indication in late 2025 or early 2026.
• Close the divestiture of the Jada System in early 2026.
• Make the remaining $10 million payment for the Oss Biotech site acquisition in the first half of 2026.
• Continue to optimize the manufacturing and supply network, including separating the supply chain from Merck through 2031.
• Address motions to dismiss in the securities lawsuits, which will then allow the stockholder derivative actions to proceed.
• The Board of Directors declared a quarterly dividend of $0.02 per share, payable on December 11, 2025, to stockholders of record on November 20, 2025.

Key Dates

Recommendation

The filing reveals severe corporate governance failures, including material weaknesses in internal controls and the forced resignation of the CEO due to improper sales practices that artificially inflated past revenues. The significant decline in net income and EPS, coupled with the expectation of adverse impact on Q4 sales from ceasing these practices, points to fundamental operational and ethical issues. While there are some positive product developments and debt management, these are heavily overshadowed by the systemic problems and the potential for ongoing regulatory scrutiny and litigation. A seasoned investor would likely view these issues as a major red flag, indicating a lack of reliable financial reporting and ethical leadership, warranting a 'sell' recommendation until the company demonstrates sustained remediation and improved, transparent performance.

Keywords

Pharmaceuticals, Women's Health, Biosimilars, SEC Filing, 10-Q, Organon, Nexplanon, Financial Results, Internal Controls, Corporate Governance, Drug Pricing, Litigation, Acquisitions, Divestitures, Biogen, Dermavant, Merck, Tofidence, Vtama, Hadlima, Singulair, Atozet, Dulera, R&D, Restructuring, Debt Management, Earnings, EPS, Revenue, Risk Factors